



## Invivyd to Participate at H.C. Wainwright's BioConnect Investor Conference

April 25, 2023

WALTHAM, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that David Hering, chief executive officer of Invivyd, is scheduled to present in a fireside chat at H.C. Wainwright's BioConnect Investor Conference on Tuesday, May 2, 2023 at 4:00 p.m. ET at the Nasdaq World Headquarters in New York, NY.

A live webcast of the fireside chat will be available in the investor section of the company's website at [investors.invivyd.com](https://investors.invivyd.com) and will be archived for 90 days following the presentation.

### About Invivyd

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect evulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. Invivyd's technology works at th intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with a high barrier to viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. Visit <https://invivyd.com/> to learn more.

### Media Contact:

Kate Burdick, Evoke Canale  
860-462-1569  
[kate.burdick@evokegroup.com](mailto:kate.burdick@evokegroup.com)

### Investor Contact:

Chris Brinzey, ICR Westwicke  
339-970-2843  
[chris.brinzey@westwicke.com](mailto:chris.brinzey@westwicke.com)